FeesSafety
Pluang+

Cannabix successfully detects fentanyl in human breath, advancing multi-drug breath testing technology.

Market News
09 Nov 2026, 15:35 WIB
GlobeNewsWire
View Source
Bullish
Cannabix successfully detects fentanyl in human breath, advancing multi-drug breath testing technology.

Cannabix Technologies announced it has successfully detected fentanyl in human breath using its Breath Collection Unit and Breath Cartridge technology, analyzed by liquid chromatography-mass spectrometry. This breakthrough marks a significant milestone as fentanyl is a potent opioid present in very low concentrations in breath, making detection challenging. The technology expands Cannabix's capabilities beyond cannabis to include multiple drugs, supporting applications in workplace safety, law enforcement, and health monitoring. The company aims to commercialize this multi-drug breath testing platform to enhance public safety and drug detection methods.

Cannabix Technologies' breakthrough in detecting fentanyl in human breath provides context for health-sector market activity. For readers following health stocks, here is Pluang's market snapshot as of Nov 09, 2026 19:41 WIB: out of 150 priced US health-sector stocks, 121 rose and 18 fell. Among notable movers, IONS dropped 20.85% to USD 31.20 with a typical hold time of 14 days, while IBRX fell 13.26% to USD 7.49 with a 6-day hold, and ABEO declined 12.47% to USD 3.65, held typically for 28 days.

More News

Microsoft to retire UWP Map Control by Nov 2026; OnTerra offers ready replacement using Azure Maps.

Microsoft to retire UWP Map Control by Nov 2026; OnTerra offers ready replacement using Azure Maps.

Microsoft will retire the backend services for its UWP Map Control and Windows Maps APIs on November 30, 2026, ending map functionality in many Windows desktop and tablet applications. OnTerra Systems, a Microsoft partner, has developed an off-the-sh...

Market News
Neutral
45 minutes ago
New combo therapy shows promise in tough metastatic breast cancer cases with high response rates

New combo therapy shows promise in tough metastatic breast cancer cases with high response rates

Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...

Company Fundamentals
Bullish
1 hour ago
Deadlines set for lead plaintiff appointments in class action lawsuits against Ensign, Netcapital, and Webull.

Deadlines set for lead plaintiff appointments in class action lawsuits against Ensign, Netcapital, and Webull.

Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...

Bearish
1 hour ago
Octave launches Attune Facilities, an AI-driven tool for managing complex multi-site operations efficiently.

Octave launches Attune Facilities, an AI-driven tool for managing complex multi-site operations efficiently.

Octave Intelligence plc has introduced Octave Attune Facilities, a cloud-based software solution designed to help organizations manage multiple sites with AI-powered tools. This platform integrates building, space, maintenance, and operational data t...

Market News
Bullish
1 hour ago
ITT Inc. price target raised to $259 after strong Q3 with 44% revenue growth and 20% earnings rise.

ITT Inc. price target raised to $259 after strong Q3 with 44% revenue growth and 20% earnings rise.

ITT Inc. reported a strong third quarter with revenue up 44% to over $1.40 billion and adjusted earnings rising 20% to $2.26 per share, driven by the SPX FLOW acquisition and 8% organic growth. Orders surged 58%, supported by aerospace, defense, and ...

Analyst Insights
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App